Although the study entailing trastuzumab treatment for gastric cancer showed a survival benefit with trastuzumab plus chemotherapy in HER2-positive gastric cancer [9], further synergistic effects could be expected by the combined use of CD137 stimulation using molecules such as rhCD137L. This evidence concerns the gene TNFRSF9 and gastric cancer.